Chiome Bioscience

Chiome Bioscience CROIC

The Cash Return on Invested Capital (CROIC) of Chiome Bioscience (4583.T) as of Oct 20, 2026 is -70.54 %. In the previous year, Cash Return on Invested Capital (CROIC) was -45.45 % — a change of 55.20% (lower).

CROIC

-70.54 %

YoY

55.20%

Last updated:

Cash Return on Invested Capital (CROIC) of Chiome Bioscience is 2025 -70.54 % . Cash Return on Invested Capital (CROIC) of Chiome Bioscience was 2024 -45.45 % . It decreases by 55.20% lower compared to the previous year.

The Chiome Bioscience CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-63.09 JPY
Jan 1, 2019
-58.66 JPY
Jan 1, 2020
-82.68 JPY
Jan 1, 2021
-108.98 JPY
Jan 1, 2022
-60.31 JPY
Jan 1, 2023
-147.60 JPY
Jan 1, 2024
-45.45 JPY
Jan 1, 2025
-70.54 JPY
The Chiome Bioscience CROIC history
YEARCROICYoY
-70.54 %+55.20%
-45.45 %-69.21%
-147.60 %+144.74%
-60.31 %-44.66%
-108.98 %+31.81%
-82.68 %+40.96%
-58.66 %-7.03%
-63.09 %+205.38%
-20.66 %-2.66%
-21.22 %-29.75%
-30.21 %+96.97%
-15.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Chiome Bioscience Stock analysis

What does Chiome Bioscience do? Chiome Bioscience, Inc. operates in Shibuya-Ku, Tokyo-To and generates revenue through two distinct business segments focused on antibody drug development. The Drug Discovery segment conducts research and development of specific antibodies based on new antigens and mechanisms, subsequently licensing these assets to pharmaceutical companies. This approach allows the firm to monetize its proprietary technology and scientific findings directly through licensing agreements. The Drug Discovery Support segment complements this by developing lead antibodies for therapeutic drugs in collaboration with pharmaceutical companies in Japan and overseas. Through these partnerships, the company provides specialized development services that support the creation of new therapeutic agents. Both segments leverage the company's Autonomous Diversifying Library (ADLib) system to facilitate the creation and refinement of antibody drugs for its clients. Chiome Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chiome Bioscience stock

Cash Return on Invested Capital (CROIC) of Chiome Bioscience is -70.54 % in 2025.

Cash Return on Invested Capital (CROIC) of Chiome Bioscience changed from -45.45 % to -70.54 %, representing a 55.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Chiome Bioscience since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Chiome Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Chiome Bioscience

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Chiome Bioscience